Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

Fig. 1

APOLLO study schematic. aKarnofsky performance status, New York Heart Association class, safety, and TTR genotyping also assessed as part of eligibility criteria. b18-month efficacy assessments: mNIS+7, NIS+7, FAP score, polyneuropathy disability stage, nerve fiber density, dermal amyloid burden, modified body mass index, timed 10-m walk test, grip strength test, Composite Autonomic Symptom Score-31 questionnaire, Norfolk Quality of Life-Diabetic Neuropathy questionnaire, EuroQol 5-Dimensions questionnaire, Rasch-built Overall Disability Scale, echocardiogram, and cardiac biomarkers. FAP familial amyloidotic polyneuropathy; IV intravenous; mNIS+7 modified NIS+7; NCS nerve conduction study; NIS Neuropathy Impairment Score

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us